AEZS News and Press, Aeterna Zentaris Inc. From 04/05/23

2023-04-05 08:48:13 ET The shares of nano-cap biotech Aeterna Zentaris ( NASDAQ: AEZS ) lost ~13% pre-market Wednesday after announcing a temporary halt to U.S. sales of its lead product Macrilen (macimorelin), effective May 23, 2023. The temporary move follows last year&#...

U . S . sales of Macrile n ® for adult use to be temporarily discontinued as of May 23, 2023 , while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen &#x...

2023-03-23 08:39:54 ET Aeterna Zentaris press release ( NASDAQ: AEZS ): Q4 GAAP EPS of -$2.56. Revenue of $2.5M (+150.0% Y/Y). The Company had $50.6 million in cash and cash equivalents at December 31, 2022. For further details see: Aeterna Zentaris GAAP EPS ...

2023-03-16 08:39:43 ET Aeterna Zentaris ( NASDAQ: AEZS ) said Pharmanovia acquired licensing rights to growth hormone therapy Ghryvelin from Aeterna's existing licensee Consilient Health. Pharmanovia acquired exclusive rights and license to commercialize Ghryvelin (ma...

Pharmanovia to acquire license to GHRYVELIN ™ from Aeter n a Zentaris’ existing licensee, Consilient Health , effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (N...

Aeterna Zentaris focuse d on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen ™ in the U . S . and Canad a Company c ontinu es to build growing body of data ac...

- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, Jan...

Live video webcast on Thursday , January 19 th at 3 :00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical comp...

Aeterna Zentaris press release ( NASDAQ: AEZS ): Q3 GAAP EPS of -$0.70 misses by $0.02 . Revenue of $1.9M (+72.7% Y/Y) beats by $0.57M . The Company had $53.8 million cash and cash equivalents at September 30, 2022 (December 31, 2021 – $65.3 million) ...

– Company ended the quarter with $ 53.8 million in cash – Driving c ontinued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc....